Flavoring Agent · CAS 110-85-0

Piperazine

FDA status: Approved. EU: not separately listed. No U.S. state has enacted a specific ban yet.

Low Risk
Score 4 of 5
Piperazine: 4/5 (Low Risk)

According to the U.S. Food and Drug Administration, Piperazine is FDA-approved, and no U.S. state has moved to restrict it independently of federal policy. Its composite safety score is 4 out of 5 (Low Risk).

Browse all Flavoring Agent additives →

The verdict

Piperazine is FDA-approved, and no U.S. state has moved to restrict it.

4/5
Low Risk
Approved
FDA status
-
EU status
0
state regulations

CAS-led regulatory snapshot

Piperazine: no OFF product match; CAS 110-85-0 is the lead registry handle on this row.

Property Value Source
CAS Number 110-85-0 CAS Registry
FDA Status Approved FDA SAFFA
EU Status Not separately listed EC 1333/2008
E-Number - EU additive register
Category Flavoring Agent FDA functional class
Composite Safety Score 4 / 5 (Low Risk) PlainIngredients methodology
EFSA ADI Not established EFSA scientific opinion
U.S. State Actions 0 states State legislative records
Tracked Products Not yet tracked Open Food Facts (US)

Values reflect official agency classifications as published by the U.S. Food and Drug Administration and the European Union's regulatory framework. See our methodology for scoring details.

What is Piperazine?

Piperazine (CAS 110-85-0) is an FDA-regulated food substance used as flavoring agent or adjuvant.

Common Uses

flavoring agent or adjuvant

Catalog-profile peer axes

Nationwide catalog-profile peers for Piperazine

Product-count (0) and safety-score (4/5) peer columns, disjoint link sets.

Score 4/5 peers (≥50 OFF products)

Nearest other additives by PlainIngredients safety score (floored at ≥50 tracked products), distinct from the count row.

8 peers

Frequently Asked Questions

Is Piperazine safe to consume?

Piperazine scores 4/5 (Low Risk). FDA status is Approved. No OFF product match yet; the distinctive registry handle is CAS 110-85-0, so this page leads with the chemical identity row rather than a shelf-prevalence claim.